Bio-Techne Corp (TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Symbol
TECH
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$11.30B
52 week range
43.2 - 72.69

Valuation

Share price
$72.40 (close of 2026-10-02)
P/E (TTM)
61.88x
Price to book
5.36x
Price to free cash flow
42.93x
Enterprise value
$11.33B
Book value per share
$13.51

Price performance

PeriodChange
1 day0.00%
5 days-0.29%
1 month+0.14%
3 months+2.22%
6 months+36.27%
Year to date+23.11%
1 year+16.60%
3 years+7.82%
5 years-41.36%
10 years+164.43%
All time+65718.18%

Members of Congress who disclosed TECH trades

April McClain Delaney · Robert Bresnahan · Julie Johnson

Super investors holding TECH

Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.) · Mairs & Power (Mairs & Power Inc) · Lee Ainslie (Maverick Capital LTD) · Ken Griffin (Citadel) · Wallace Weitz (Weitz Investment Management) · George Soros (Soros Fund Mgmt) · Henry Ellenbogen (Durable Capital Partners LP) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
8.63%
Return on invested capital
9.05%
Return on assets
7.03%
Return on capital employed
10.40%
Gross margin
65.77%
Net margin
14.97%
EBITDA margin
28.74%
Revenue growth
-0.38%
Net income growth
147.77%
Free cash flow growth
2.60%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.33%
Current ratio
4.55x
Net debt to EBITDA
0.07x

Latest reported year

Period end
2026-06-30
Fiscal year
2026
Revenue
$1.22B
Cost of revenue
$415.97M
Gross profit
$799.07M
EBITDA
$349.25M
Net income
$181.86M
Earnings per share
$1.17
Shares outstanding
155.96M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2026-06-30$1.22B$799.07M$181.86M$1.17
2025-06-30$1.22B$790.27M$73.40M$0.47
2024-06-30$1.16B$769.73M$168.10M$1.07
2023-06-30$1.14B$769.82M$285.26M$1.81
2022-06-30$1.11B$756.50M$272.05M$1.73
2021-06-30$931.03M$632.85M$140.41M$0.91
2020-06-30$738.69M$483.19M$229.30M$1.50
2019-06-30$714.01M$473.49M$96.07M$0.64
2018-06-30$642.99M$432.14M$126.15M$0.84
2017-06-30$563.00M$374.54M$76.09M$0.51

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2026-06-3065.77%14.97%8.63%9.05%
2025-06-3064.80%6.02%3.83%3.51%
2024-06-3066.41%14.50%8.13%8.10%
2023-06-3067.72%25.10%14.51%11.08%
2022-06-3068.42%24.61%15.99%16.81%
2021-06-3067.97%15.08%8.94%15.98%
2020-06-3065.41%31.04%16.60%9.19%
2019-06-3066.31%13.46%8.24%12.92%
2018-06-3067.21%19.62%11.69%15.18%
2017-06-3066.53%13.51%8.01%10.70%

Cash and debt by year

Period endCash
2026-06-30$264.71M
2025-06-30$162.19M
2024-06-30$152.86M
2023-06-30$204.31M
2022-06-30$247.03M
2021-06-30$231.55M
2020-06-30$270.89M
2019-06-30$166.03M
2018-06-30$181.75M
2017-06-30$157.71M

Free cash flow by year

Period endFree cash flowStock-based compensation
2026-06-30$263.22M$41.37M
2025-06-30$256.55M$40.83M
2024-06-30$236.10M$38.04M
2023-06-30$216.15M$39.23M
2022-06-30$280.36M$42.18M
2021-06-30$307.86M$48.98M
2020-06-30$153.47M$32.37M
2019-06-30$156.21M$32.28M
2018-06-30$149.43M$28.24M
2017-06-30$128.54M$14.63M

Dividend history

Most recent payment
2026-08-24
Paid in the last twelve months
$0.32
Payment dateDividend per share
2026-08-24$0.08
2026-05-18$0.08
2026-02-13$0.08
2025-11-17$0.08
2025-08-18$0.08
2025-05-19$0.08
2025-02-14$0.08
2024-11-08$0.08

Investor relations

Next earnings report

Next confirmed report
2026-11-04
Consensus EPS estimate
$0.40

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-12Jun/2026$0.46
2026-08-05Jun/2026$0.46
2026-05-06Mar/2026$0.48
2026-02-04Dec/2025$0.34
2025-11-05Sep/2025$0.36
2025-08-06Jun/2025$0.46
2025-05-07Mar/2025$0.45
2025-02-05Dec/2024$0.33

Filings and sources

Company website
bio-techne.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Incyte Corp (INCY) · Insmed Inc (INSM) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA) · Agilent Technologies, Inc. (A)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades